Can quantifying the extent of ‘high grade’ features help explain prognostic variability in anaplastic astrocytoma?
- 30 December 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in British Journal of Neurosurgery
Abstract
Both phenotypic and genotypic variations now underpin glioma classification, thus helping to more accurately guide their clinical management. However, WHO Grade III anaplastic astrocytoma (AA) remains an unpredictable, heterogeneous entity; displaying a variable prognosis, clinical course and treatment response. This study aims to examine whether additional tumour characteristics influence either overall survival (OS) or 3-year survival in AA. Data were collected on all newly diagnosed cases of AA between 2003 and 2014, followed up for a minimum of 3 years. Molecular information was obtained from case records and if missing, was re-analysed. Histological slides were independently examined for Ki-67 proliferation index, cellularity and number of mitotic figures. Kaplan–Meier and Cox regression analyses were used to assess OS. In total, 50 cases were included with a median OS of 14.5 months (range: 1–150 months). Cumulative 3-year survival was 31.5%. Median age was 50 years (range: 24 − 77). Age, IDH1 mutation status, lobar location, oncological therapy and surgical resection were significant independent prognostic indicators for OS. In cases demonstrating an OS ≥ 3 years (n = 15), Ki-67 index, number of mitotic figures and percentage areas of ‘high cellularity’ were significantly reduced, i.e. more characteristic of lower-grade/WHO Grade II glioma. IDH1 status, age, treatment and location remain the most significant prognostic indicators for patients with AA. However, Ki-67 index, mitotic figures and cellularity may help identify AA cases more likely to survive < 3 years, i.e. AA cases more similar to glioblastoma and those cases more likely to survive > 3 years, i.e. more similar to a low-grade glioma.Keywords
This publication has 21 references indexed in Scilit:
- The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)IEEE Transactions on Medical Imaging, 2014
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011Neuro-Oncology, 2014
- The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier CoefficientsAmerican Journal of Epidemiology, 2013
- A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictorsJournal of Neuro-Oncology, 2012
- Clustering methods applied in the detection of Ki67 hot-spots in whole tumor slide images: An efficient way to characterize heterogeneous tissue-based biomarkersCytometry Part A, 2012
- High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Anaplastic astrocytoma in adultsCritical Reviews in Oncology/Hematology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Epidemiology and molecular pathology of gliomaNature Clinical Practice Neurology, 2006
- Aberrant p53 Expression Does Not Correlate with the Prognosis in Anaplastic AstrocytomaNeurosurgery, 1995